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ABSTRACT
Patient and public involvement (PPI) in research is
increasingly required, although evidence to inform its
implementation is limited.
Objective: Inform the evidence base by describing how
plans for PPI were implemented within clinical trials and
identifying the challenges and lessons learnt by research
teams.
Methods:We compared PPI plans extracted from clinical
trial grant applications (funded by the National Institute
for Health Research Health Technology Assessment
Programme between 2006 and 2010) with researchers’
and PPI contributors’ interview accounts of PPI
implementation. Analysis of PPI plans and transcribed
qualitative interviews drew on the Framework technique.
Results: Of 28 trials, 25 documented plans for PPI in
funding applications and half described implementing PPI
before applying for funding. Plans varied from minimal to
extensive, although almost all anticipated multiple modes
of PPI. Interview accounts indicated that PPI plans had
been fully implemented in 20/25 trials and even expanded
in some. Nevertheless, some researchers described PPI
within their trials as tokenistic. Researchers and
contributors noted that late or minimal PPI engagement
diminished its value. Both groups perceived uncertainty
about roles in relation to PPI, and noted contributors’ lack
of confidence and difficulties attending meetings. PPI
contributors experienced problems in interacting with
researchers and understanding technical language.
Researchers reported difficulties finding ‘the right’ PPI
contributors, and advised caution when involving
investigators’ current patients.
Conclusions: Engaging PPI contributors early and
ensuring ongoing clarity about their activities, roles and
goals, is crucial to PPI’s success. Funders, reviewers and
regulators should recognise the value of preapplication
PPI and allocate further resources to it. They should also
consider whether PPI plans in grant applications match a
trial’s distinct needs. Monitoring and reporting PPI before,
during and after trials will help the research community to
optimise PPI, although the need for ongoing flexibility in
implementing PPI should also be recognised.
INTRODUCTION
There are several schools of thought regard-
ing why patient contributors should be
involved as advisors or partners in healthcare
research, rather than just as participants.
Ethical and political arguments for patient
partnerships are based on values such as dem-
ocracy, accountability and empowerment.1–3
Alongside these values are pragmatic argu-
ments which revolve around the belief that
patient and public involvement (PPI) can
enhance the relevance, validity, quality and
success of research.1–5 The growth in PPI
nationally and internationally6–8 is reﬂected
by its increasing assimilation into grant appli-
cations, with funding bodies encouraging
researchers to submit plans for PPI in order
to obtain funding.2 9–12 Such developments
have branched out into other realms
Strengths and limitations of this study
▪ This was the first study to examine whether
plans for patient and public involvement (PPI),
as documented in trialists’ grant applications,
were subsequently implemented.
▪ Semistructured interviews with chief investiga-
tors and patients allowed us to identify chal-
lenges to implementing PPI, and lessons learnt,
from a range of informant perspectives.
▪ The study benefited from the inclusion of a com-
bination of trials which had ended at the time of
the interviews, and those which were ongoing.
▪ Some informants struggled to recall events per-
taining to PPI for trials which had ended—a
drawback of retrospective study designs.
▪ We used a historical cohort of trials, funded 4–
8 years previously. The emphasis on PPI has
grown over these years, thus our findings may
not fully reflect the planning and implementation
of PPI in trials funded recently.
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including patient involvement in academic publishing,
for instance within The BMJ.13
For PPI contributors, getting involved in research has
been reported to lead to ‘personal development’ such as
boosting conﬁdence, empowerment and a sense of
purpose.14 Similarly there can be personal beneﬁts for
researchers who have reported that their attitudes,
values and beliefs about the worth of PPI had been
heightened as a result of such involvement.15 However,
as well as being a vehicle for improving research validity,
there are indications that ‘patient inﬂuence’ can pose a
potential threat to the validity of research if it is not
drawn on appropriately.2 For example, PPI in technical
decisions may result in worse as opposed to improved
project outcomes.16
Challenges to the realisation of plans for PPI include
debate regarding its purpose, lack of evidence regard-
ing the impact of PPI, complexities in researchers and
contributors sharing power, and difﬁculties in ensuring
sufﬁcient resources for PPI.4 10 15 17–19 Alongside such
challenges are uncertainties regarding how best to plan
PPI. Guidance drawing on the opinions and experi-
ences of those involved in PPI activity within trials is
available17 20 and a recent review has examined case
studies of PPI in the design and conduct of trials.21
However, the evidence base is limited in terms of the
range of trials, researchers and patients that have
informed this previous work, and there has been no sys-
tematic evaluation of the extent to which trialists’ inten-
tions for PPI are put into practice. This is an important
gap in view of the above challenges and the increased
onus on researchers to build plans for PPI into their
grant applications. Such plans run the risk of being
uninformed due to the lack of evidence across a range
of trial contexts and informant perspectives. In this
paper we aim to inform practice for trialists and contri-
butors by describing the extent to which documented
PPI plans were implemented within a range of clinical
trials and identifying the challenges met and the
lessons learnt. Given that funding bodies encourage
PPI, we also aim to inform policy with regard to post-
trial scrutiny of PPI in terms of processes, facilitators
and barriers, and impacts.
METHODS
Terminology
We use the term ‘PPI contributors’ or ‘contributors’ rather
than the more commonly used term ‘PPI representatives’
to avoid implying that a few individuals can represent the
perspectives of diverse patient groups and members of the
public, and ‘informants’ to refer collectively to the
researchers (primarily chief investigators (CIs)) and PPI
contributors. We use the terms ‘documented plans’ to
refer to the plans for PPI which were written into the
funding application or study protocol and ‘expectations’
to refer to what the trial team expected PPI to achieve, as
described by the researchers during the interviews.
Design
This qualitative study formed part of the ‘Evidence base
for Patient and public Involvement in Clinical trials’
(EPIC) project. EPIC aimed to investigate PPI in a
cohort of randomised controlled trials (RCTs) funded
by the National Institute for Health Research (NIHR)
Health Technology Assessment (HTA) programme
between 2006 and 2010. We have described the methods
in full elsewhere.22 In summary, EPIC comprised four
phases. Phase 1 examined trialists’ plans for PPI as
described within their outline and full funding applica-
tions. Phase 2 was a questionnaire survey of CIs’ and PPI
contributors’ opinions and activities concerning PPI.
Phase 3 involved qualitative interviews with CIs, PPI con-
tributors and trial managers (TMs). Phase 4 examined
the role of clinical trials units in identifying and support-
ing PPI activity in trials.
The current paper draws mostly on data from phases 1
and 3 and, to a lesser extent, phase 2. EPIC had a
patient advisory group, consisting of ﬁve people with
experience of being a patient or a carer, previous PPI
contribution in trials and lay review of funding applica-
tions and membership of funding panels. The National
Research Ethics Service (NRES) advised that EPIC did
not require NRES ethics approval; we therefore sought
and obtained a favourable ethical opinion from the
University of Liverpool Research Ethics Committee (Ref:
RETH000489).
Sampling and recruitment for semistructured interviews
We emailed CIs at the address given on their grant appli-
cation form. We aimed for a diverse sample of CIs for
interview, based on their responses to questions within
the CI survey concerning motivations for including PPI
and its perceived impact, although we ultimately invited
all but three of the CIs who had responded to the survey
and expressed an interest in being interviewed. Three
CIs were not invited because of delays in responding to
the survey. We identiﬁed and invited PPI contributors to
be interviewed through the CIs, chairs of steering com-
mittees and advertisements on PPI websites. Potential
informants were sent an email with an information
leaﬂet which included the purpose of the qualitative
study.
LD conducted semistructured telephone interviews
with informants between April and November 2013,
seeking their views and experiences of PPI within their
trial. The interviewer had a BSc and MRes in psychology,
and previous experience and training of conducting and
analysing qualitative interviews. Apart from the recruit-
ment emails, the interviewer had not established a rela-
tionship with the participants prior to the start of the
study. LD was new to the ﬁeld of patient involvement in
research and sought to maintain an open-minded
approach in exploring its implementation in trials. The
interviews were audio-recorded, transcribed, anonymised
and checked for accuracy. The interviewer used topic
guides which were reviewed by our patient advisory
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group, and developed in light of ongoing data analysis.
The interviews were conversational in nature, enabling
informants to freely describe their experiences and raise
topics which we had not anticipated. Informants gave
their informed consent for the interviews to be audio-
recorded and analysed. During the interviews we asked
all informants to describe the type of PPI activity that
had taken place in the trial. In order to foster rapport
between informant and interviewer we intentionally
avoided direct questions about why any plans were not
implemented. However, we did ask CIs whether they
would do anything differently regarding PPI if they were
to start the trial again. We asked PPI contributors about
any challenges and explored their views on how PPI
could be enhanced in future trials. No ﬁeld notes or
repeat interviews were undertaken.
Data sources
Primary sources of data were: trial documentation (full
application forms, reviewer comments, detailed project
descriptions and study protocols), from which we
extracted data about plans for PPI; CI and PPI contribu-
tor interview transcripts, from which we determined
whether the documented plans were implemented.
Secondary sources of data were: outline application
forms, CI survey responses and TM interview transcripts.
We used the secondary sources in cases of ambiguity, that
is, where it was unclear from the primary sources whether
aspects of a particular set of plans had been implemen-
ted. We also used the secondary sources to elucidate the
illustrative examples that we present in the results below.
Analysis
To be eligible for the current analysis at least one
source of interview data was required from either the
CI or PPI contributor, as well as the grant application
documents from which we identiﬁed and extracted
data regarding plans for PPI. To determine the extent
to which these documented plans were implemented
we focused equally on the qualitative data from the CI
and PPI contributor interview transcripts. In cases of
ambiguity we consulted the TM interview transcripts,
where available. We focused on identifying and analys-
ing patterns within the data, to inform our interpreta-
tions,23 and as appropriate the criterion of catalytic
validity whereby qualitative research should not just
describe but aim to inform practice.24 For the purposes
of determining the PPI activity undertaken, challenges
met and lessons learnt, one author (DB) ﬁrst famil-
iarised herself with the data by reading the transcripts
several times, before drawing on the framework tech-
nique25 to develop and apply open codes to the inter-
view data. She then grouped the codes into broader
categories within the framework and compared these
with data extracted from the documented plans. Other
members of the EPIC team who were familiar with the
interview transcripts and documented plans examined
the early stages and ongoing reﬁnements of the
descriptive coding framework, as well as the tabulated
comparisons of planned and implemented PPI. CG
had analysed the CI survey and application forms,22
and LD and BY had analysed the interview data to
explore the perceived impact of PPI, thus providing
conﬁdence in the credibility and ‘conﬁrmability’ of the
present ﬁndings.26 Moreover, DB analysed the interview
transcripts before looking at the documented plans
that had been extracted from the grant application
forms, thus helping to reduce the chances that the
documented plans would unduly inﬂuence her inter-
pretations of informants’ interview accounts of PPI.
Transcripts were not returned to informants for
‘member checking’ as interpretation of such feedback
is problematic.27 A description of the coding frame is
available on request.
We provide illustrative quotes from a range of inter-
views and trial documents. Identiﬁcation codes signify
the source of informant quotes based on their group
(ie, CI or PPI contributor) followed by their anonymised
trial identiﬁcation number. Where more than one PPI
contributor was interviewed for the same trial, we indi-
cate as PPI 1 or PPI 2. Codes for documented plans
refer to anonymised trial identiﬁcation numbers. We
replaced identifying text within quotes with anonymised
text, and use […] to signify abridged quotes.
In the sections that follow we refer to the three different
types of PPI role, identiﬁed by our earlier analysis of infor-
mants’ accounts of the impact of PPI on the trials. The
identiﬁed PPI roles were: oversight, typically characterised
by the formal presence of a PPI contributor on the trial
steering committee (TSC), with infrequent involvement;
managerial, also usually a formal role but with more
regular involvement, for example as co-investigator or
member of the trial management group; and responsive
roles, which tended to be less formal, often with more
than one contributor, or making use of advisory panels
and focus groups as and when problems occurred.
RESULTS
PPI plans: from intentions to actions
As illustrated in ﬁgure 1, 28 trials were eligible for inclu-
sion in the current analysis. We conducted interviews
with the CI and a PPI contributor in 9 of the 28 trials,
with the CI only in 12 trials and a PPI contributor only
in 7 trials. One PPI contributor was involved in two of
the trials in this sample, while a further two trials had
two PPI contributor interviews. We also conducted inter-
views with 10 TMs and consulted 1 of these transcripts
where there was ambiguity in CI/PPI accounts regarding
whether all plans for PPI had been implemented.
Interviews lasted 45 min on average. Where multiple
sources of interview data were available, for example,
from a CI and a PPI contributor, there were no major
discrepancies between accounts.
As shown in table 1, all but 3 of the 28 trials had docu-
mented plans for PPI in their grant application or
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protocol or both. These documents varied greatly
regarding the extensiveness of PPI activity planned and
precision with which plans were described, from vague
references to activities that hinted at PPI, “We will make
use of two primary care research networks and an
[intervention-speciﬁc] research network” (trial 115), to
statements that were quite precise, “The [Society] con-
ﬁrmed their willingness to represent their members
through steering committee membership […] and to
help in the construction of the MREC application and
patient information leaﬂets” (trial 102). On the basis of
informants’ interview accounts, all trials subsequently
incorporated some form of PPI and it was clear from
the interviews that documented plans were fully imple-
mented in most (20/25) instances regardless of whether
the plans were vague or precise, minimal or extensive.
The three trials without documented plans did proceed
to include some PPI activity, perhaps prompted, to an
extent, by comments from peer reviewers who had
remarked on the lack of PPI plans in each case. This is
particularly likely in trial 2. Here, the grant application
referred to prefunding PPI and when interviewed the CI
spoke of initial ‘tokenism’ and ‘ignorance’ about how
PPI should work. A further three trials expanded on
documented plans, giving a total of six trials which had
seen addition or expansion of plans for PPI.
Despite informants indicating that most of the docu-
mented plans for PPI had been implemented, some
revealed no personal expectations for PPI and spoke of
using it as a means of ‘ticking the right boxes’. This
raises questions about the motivations behind the PPI
plans in some grant applications. As noted, we had previ-
ously identiﬁed three types of PPI roles within our
cohort of RCTs: oversight, managerial and responsive,22
and many trials built into their plans a combination of
these roles. On the basis of informants’ accounts it
appeared that six trials largely conﬁned PPI to an over-
sight mode of involvement, although some had hinted
at other modes in their applications. We begin by exam-
ining what happened in these trials.
Figure 1 EPIC trials eligible for
analysis comparing PPI plans
and implementation. *There were
17 contributor interviews for 17
trials, although 1 PPI contributor
was in 2 trials while a further 2
trials had 2 PPI contributor
interviews. CI, chief investigator;
PPI, patient and public
involvement; EPIC, Evidence
base for Patient and public
Involvement in Clinical trials.
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Table 1 Summary of planned and implemented PPI activity by type of role
Trial ID
Status
(trial ended or ongoing)
Mode(s) Summary of planned activity*
PPI
plans fully
implemented? Accounts of ‘actual’ PPI activity†
(A) Trials which had a chiefly oversight mode (n=6)
115
Ended
Oversight
Unclear whether trial had PPI co-applicants although service user contributed to
the proposal
“We will make use of two primary care research networks and an exercise research
network”
U Had PPI membership on TSC but unclear in terms of ‘making use of research
networks’. CI had expectations for and prior experience of PPI; no challenges. PPI
contributor had prior experience of PPI; challenges (problems getting to meetings
because of health)
36
Ongoing
Oversight
No PPI co-applicants
Patient rep was named as a member of the TSC
In response to referee comments, applicants stated they would consider increasing
the number of PPI contributors on the TSC from one to two “to provide mutual
support”
Y Has two PPI contributors on TSC but CI talked of ‘no direct impact’ and ‘ticking a
political box’. CI had no expectations for but had prior experience of PPI;
challenges (“only very minor such as patient rep not having email”). PPI contributor
had no prior experience of PPI; challenges ( jargon)
65
Ended
Oversight
No PPI co-applicants
“We will have lay representation on the TSC. We will use the expertise and contacts
of our panel to form focus groups to assist in the understanding and dissemination
of findings”
U Had PPI membership on TSC as planned but unclear whether implemented plans
regarding the use of the panel/focus groups to understand/disseminate findings. CI
felt no direct PPI overall. CI had no expectations for but had prior experience of
PPI; challenges (getting the right people engaged; difficult target population;
unable to get enough early engagement to inform changes to study design). No
PPI contributor interview
2
Ongoing
Oversight
No PPI co-applicants
No documented plans. Did refer to PPI that had occurred prior to grant application
NA Has PPI membership on TSC. CI had no expectations for but had prior experience
of PPI although spoke of initial “tokenism” and “ignorance” about what to expect of
PPI in current trial; challenges (“just the slight feeling that we were taking up her
time”). No PPI contributor interview
64
Ended
Oversight
No PPI co-applicants
“We have identified two people with [condition] who have agreed to be consumer
reps and have advised on the development of this proposal”
Y No CI interview. Had PPI membership on TSC. PPI contributor had no prior
experience of PPI; challenges ( jargon, unable to attend all the meetings, some
team members were felt to lack understanding)
96
Ongoing
Oversight
No PPI co-applicants
“A patient representative will provide input into the design of patient literature and
trial presentations to a general audience as well as providing a patient’s perspective
at TSC and [Data Monitoring and Ethics Committee] meetings. TSC will meet two
to three times a year”
Y No CI interview. Has PPI membership on TSC. ‘Keep in contact’ approximately
twice a year. PPI contributor had no prior experience of PPI; no challenges
(B) Trials which included a managerial mode (n=14)§
20
Ended
Managerial + responsive
Had a PPI co-applicant
“The research team will convene a steering group of research and service users.
This will meet three times during the study and will provide an opportunity for the
research team to consult about research design and methods for data collection,
choice of outcomes and methods for data analyses. The TSC will have an
important role in interpreting initial findings and developing dissemination strategies.
Consultation with young people and parents will be carried out in intervention and
comparison clinics using focus groups. The views gathered in these groups will
inform the development of research procedures (eg, consent, outcome measures),
tools for data collection and the process evaluation. Focus groups will also provide
opportunity for young people to contribute to interpretation of study findings. Further
consultation with young people will involve piloting all research tools to ensure
acceptability and appropriateness”
Y Had input from four PPI contributors at different times. Membership on TSC.
Sought additional input when struggling with particular issues. CI had expectations
for and prior experience of PPI; challenges (having a contributor who was a patient
of the lead PI—‘conflict of roles’; frustration at inability to integrate contributors’
ideas regarding questionnaire which was a validated instrument and therefore
could not be altered). PPI contributor had no prior experience except as charity
member; no challenges
21
Ended
Oversight + managerial +
responsive
Had a PPI co-applicant “User and consumer groups have discussed the application
and suggested changes to protocol which we have accepted. In the trial the groups
will be asked to help with development of info leaflets, consent forms, letters,
questionnaire design. The groups were very keen that a user was a collaborator on
grant application. The team includes [name], a consumer representative who is
chair of [Consumer Research Group], works with the [condition] Association and
the [Research Network]”
Y Had PPI co-applicant. Plans expanded (in terms of recruitment, analysis,
interpretation of results, dissemination). CI had expectations for and prior
experience of PPI; challenges (‘poaching’ of contributors; stress about funding/
paying contributors for their time if in receipt of benefits/pension; disagreement
with funders regarding contributor’s activities). PPI contributor had prior experience
of PPI; challenges (time; being in demand)
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Table 1 Continued
Trial ID
Status
(trial ended or ongoing)
Mode(s) Summary of planned activity*
PPI
plans fully
implemented? Accounts of ‘actual’ PPI activity†
27
Ongoing
Oversight + managerial +
responsive
No PPI co-applicants
“We will include two [condition] patients to act in an advisory capacity. They will be
invited to attend all collaborator meetings and quarterly trial management meetings.
We will disseminate project information and findings for patients and patient groups”
Y Has PPI membership on trial management, steering, and data monitoring groups.
CI had expectations for and prior experience of PPI; challenges (finding
contributors). Two PPI contributors interviewed had no prior experience of PPI;
challenges (some doctors do not want to understand your point of view; jargon;
they talk about things you have gone through as a patient in a dispassionate way)
16
Ongoing
Oversight + managerial
Had a PPI co-applicant
“[Name] is Head of Policy and Research at [name of a national trust]. She has
extensive experience of representing the views of the consumer in clinical research
and at local and national policy levels. [She] will ensure that the perspective of the
consumer remains central during all stages of the trial. Independent user
representative(s) will be included on the TSC. The role of user representatives on
the Data Monitoring Committee is more difficult because of the complex technical
nature of the role of this committee. However, once a Chair of the Data Monitoring
Committee has been appointed, we will discuss with the Chair their views about the
composition of this committee, and specifically the role of users. User groups at
annual [User Group meeting] have commented on the proposal and several groups
have agreed to help develop the information and consent process”
Y Has PPI co-applicant. CI had expectations for and prior experience of PPI;
challenges (finding the right people; consumer groups with a specific interest and
so may be ‘partisan’). PPI contributor had prior experience of PPI; challenges
( jargon; infrequent meetings ‘not much to build a relationship on’)
5
Ongoing
Oversight + managerial
Had a PPI co-applicant
“We have identified consumer representation from participants in our previous
studies, and one, who is a grant applicant, has contributed to the development of
the application, trial design and study documentation, particularly the information to
be provided about the safety and efficacy of [device]. We have identified a
consumer representative to ensure that patients’ views are incorporated into the
design from the start. She is a grant applicant and has already contributed to the
trial design and the participant information sheet. Consumer groups will ensure all
relevant issues are covered, that patient information and survey instruments are
acceptable and outcome measures relevant”
Y Has PPI co-applicant. CI had no expectations for but had prior experience of PPI;
challenges (finding the right people; finding people without an ‘axe to grind’). Two
PPI contributors interviewed had no prior experience of PPI; challenges ( jargon,
not liking flying)
10
Ongoing
Oversight + managerial +
responsive
Had PPI co-investigator
No documented plans
NA Has co-investigator (from local authority). Consulted with parents regarding timing
of intervention. Has a contributor on TSC. When getting low response, approached
(education professionals) for advice. CI had expectations for PPI; said had no
formal PPI experience ‘only informal’; challenges (sometimes difficult to get in
touch with co-investigator contributor due to other commitments). PPI contributor
had prior experience of PPI; challenges (concern about ‘being too pernickety’)
4
Ended
Managerial
No PPI co-applicants
“A project management steering group […] will include all co-applicants, research
assistants and user representatives. User representatives will be involved in the
development, implementation and interpretation of the study. This involvement will
include: advice on recruiting patients, invitation letters, the design of information
leaflets, and research instruments, piloting assessments, helping to assess
progress, and contributing to the evaluation of the project, the interpretation of
findings and the dissemination of results. User representatives will be invited to
project steering group meetings and also provide assistance in each centre”
Y Had 2 PPI members on the trial management group. Involved in most activities as
envisaged and while unclear from CI interview about plans for interpretation of the
study, responses to the CI survey indicate that analysis had not yet started. CI had
expectations for and prior experience of PPI; no challenges. No PPI contributor
interview
7
Ongoing
Oversight + managerial +
responsive
Had a PPI co-applicant
“We will include patients and carers as active participants in the research at all
stages. [Name] and [name] have taken the role of patient representatives during the
preparation of this research proposal. As the relevant service users are highly likely
to be frail, we will use innovative methods to allow full involvement. We will not
expect attendance at full research team meetings by patients or carers, although
our patient representatives may bring their views to the team meetings, following
Y Has PPI co-applicant and membership on trial management, steering and data
monitoring groups. Also consult separate panel of service users for specific issues.
CI had expectations for and prior experience of PPI; challenges (identifying/
engaging the right people; some less able to articulate their views; some wanting
to do something impossible; difficulty getting other staff to understand or prioritise
PPI). No PPI contributor interview
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Table 1 Continued
Trial ID
Status
(trial ended or ongoing)
Mode(s) Summary of planned activity*
PPI
plans fully
implemented? Accounts of ‘actual’ PPI activity†
meetings with individual or groups of service users in other forums. We identified
service users to be involved in this trial through the [names of 2 organisations]. Our
named co-applicant will attend Trial Management Group meetings throughout the
study in order to contribute the service user perspective at all stages. In addition,
[name] is a named co-applicant to the study and will play a role in ensuring that a
patient focus is maintained throughout the study. We also plan to seek further
views through a wider stakeholder group that will feed into the Trial Management
Group through a nominated representative”
14
Ongoing
Managerial
Had a PPI co-applicant
“Co-applicant with an academic interest in representing patients’ perspectives in the
design and conduct of health care research will advise the research team on the
development of processes and materials which take into account patient concerns”
Y Has PPI co-applicant but CI felt it was a ‘tick box’ exercise. CI had no expectations
for or prior experience of PPI; challenges (meetings attendance; lack of
engagement). No PPI contributor interview
41
Ongoing
Oversight + managerial +
responsive
Had a PPI co-applicant
“A representative from [charity] has been involved in preparatory work and will be
nominated as a member of the TSC. A minimum of two users will be invited to be
part of the project team. A virtual user advisory group will be developed to provide
further user support as appropriate. User involvement will contribute to: TSC and
project management decisions on all stages of the project; project approval;
refinement of self-assessment tools and advice package, exercise intervention;
training events for health professionals; interpretation of findings; evaluation of user
involvement; dissemination”
Y Has PPI co-applicant. Trial has 2 PPI contributors although CI feels no strong PPI
input overall. Unclear whether CI had expectations for PPI; had no prior experience
of PPI; challenges (contributors with an ‘axe to grind’; contributors’ lack of
confidence about contributing at meetings). No PPI contributor interview
55
Ended
Oversight + managerial
Had a PPI co-applicant
“Patient reps have been very much involved in the preparation of this bid since its
inception. The lead service user joined the TSG, will co-ordinate involvement of
service users in the consumer panel and report their views to the TSG. Members of
the consumer panel have commented on the current proposal and will be asked to
comment on specific design and / or management issues during the course of the
study. In particular, their views have been, and will continue to be sought during the
preparation of patient information leaflets and posters, and in the preparation of
study newsletters. They will be asked to help with dissemination of research
findings”
Y Had PPI co-applicant. Planned to involve consumer panel in dissemination of the
findings. This did not happen but PPI ‘evolved’ because the team disseminated
through other partners, that is, other patients they were ‘working with in the field’ by
that time. Other plans were adhered to. CI had expectations for and prior
experience of PPI; challenges (not realising how much training the panel might
need; not being clear about expectations of the main contributor; panel feeling
ostracised; difficulty getting trial manager to understand importance and use of the
patient panel in the early stages). No PPI contributor interview
15
Ended
Oversight + managerial
Had a PPI co-applicant
“[Name], a former patient and lay member of the advisory panel, has been fully
involved in the application process as a co-applicant and will be a full, active and
vocal member. The trial will be guided by a group of respected and experienced
critical care personnel and trialists as well as a ‘lay’ representative”
Y No CI interview. PPI co-applicant helped to prepare paperwork for funding; also
member of TSC. PPI contributor had prior experience of PPI; challenges ( jargon)
34‡
Ended
Managerial
Had a PPI co-applicant
“This proposal has been reviewed by our patient service user group and any
opinions and comments incorporated. A patient representative will attend TSC
meetings and be directly involved in decision making of trial processes and then
relay back information to the [user groups] on a regular basis. Our Service Users
group will be involved in all aspects of project design, data collection, analysis and
dissemination”
U No CI interview. Had PPI co-applicant who appears to have been involved as
intended, but it is not clear whether plans to involve the user group in data
collection, analysis and dissemination were implemented. PPI contributor had prior
experience of PPI; challenges (not being involved from the start)
18‡
Ongoing
Managerial
Unclear whether had PPI co-applicants
Same plans as trial 34 above‡
U As above except unclear whether the informant was a co-applicant on this
particular trial
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Table 1 Continued
Trial ID
Status
(trial ended or ongoing)
Mode(s) Summary of planned activity*
PPI
plans fully
implemented? Accounts of ‘actual’ PPI activity†
(C) Trials which included a responsive role (n=14)§
20
Ended
Managerial + responsive
Had a PPI co-applicant
“The research team will convene a steering group of research and service users.
This will meet three times during the study and will provide an opportunity for the
research team to consult about research design and methods for data collection,
choice of outcomes and methods for data analyses. The TSC will have an
important role in interpreting initial findings and developing dissemination strategies.
Consultation with young people and parents will be carried out in intervention and
comparison clinics using focus groups. The views gathered in these groups will
inform the development of research procedures (eg, consent, outcome measures),
tools for data collection and the process evaluation. Focus groups will also provide
opportunity for young people to contribute to interpretation of study findings. Further
consultation with young people will involve piloting all research tools to ensure
acceptability and appropriateness”
Y Had input from four PPI contributors at different times. Membership on TSC.
Sought additional input when struggling with particular issues. CI had expectations
for and prior experience of PPI; challenges (having a contributor who was a patient
of the lead PI—‘conflict of roles’; frustration at inability to integrate contributors’
ideas regarding questionnaire which was a validated instrument and therefore
could not be altered). PPI contributor had no prior experience except as charity
member; no challenges
101
Ended
Oversight + responsive
No PPI co-applicants
“We will convene user group meetings in each locality during the pilot study, we will
organise separate focus groups to explore expectations of treatment. We have a
commitment from panels of users/experts including representatives from relevant
charities to meet annually during the study to advise on its conduct. We will have
lay representation on the TSC”
Y Had PPI membership on TSC and consulted with wider groups as planned. CI felt
PPI was under utilised and said “people above me in the scheme of things may
see it as a tick box exercise.” CI had no expectations for PPI; unclear regarding
prior experience of PPI; challenges (finding suitable people, ‘pinning people down’,
some may find it daunting whereas ‘professional PPI reps’ do not). PPI contributor
had prior experience of PPI; no challenges
21
Ended
Oversight + managerial +
responsive
Had a PPI co-applicant
“User and consumer groups have discussed the application and suggested
changes to protocol which we have accepted. In the trial the groups will be asked
to help with development of info leaflets, consent forms, letters, questionnaire
design. The groups were very keen that a user was a collaborator on grant
application. The team includes [name], a consumer representative who is chair of
[Consumer Research Group], works with the [condition] Association and the
[Research Network]”
Y Plans expanded (in terms of recruitment, analysis, interpretation of results,
dissemination). CI had expectations for and prior experience of PPI; challenges
(‘poaching’ of contributors; stress about funding/paying contributors for their time if
in receipt of benefits/pension; disagreement with funders regarding contributor’s
activities). PPI contributor had prior experience of PPI; challenges (time; being in
demand)
27
Ongoing
Oversight + managerial +
responsive
No PPI co-applicants
“We will include two [condition] patients to act in an advisory capacity. They will be
invited to attend all collaborator meetings and quarterly trial management meetings.
We will disseminate project information and findings for patients and patient groups”
Y Has PPI membership on trial management, steering, and data monitoring groups.
CI had expectations for and prior experience of PPI; challenges (finding
contributors). Two PPI contributors interviewed had no prior experience of PPI;
challenges (some doctors do not want to understand your point of view; jargon;
they talk about things you have gone through as a patient in a dispassionate way)
10
Ongoing
Oversight + managerial +
responsive
Had PPI ‘co-investigator’
No documented plans
NA Consulted with parents regarding timing of intervention. Has a contributor on TSC.
When getting low response, approached (education professionals) for advice. CI
had expectations for PPI; said had no formal PPI experience ‘only informal’;
challenges (sometimes difficult to get in touch with co-investigator contributor due
to other commitments). PPI contributor’s challenges: concern about ‘being too
pernickety’
9
Ended
Oversight + responsive
Unclear whether there were PPI co-applicants
“The TSC will include a patient representative, [name], who has acted in this
capacity in several other large-scale trials and is aware of issues that might be
raised from the lay perspective. The patient information leaflet and consent form
have been reviewed by potential service users, and their comments taken into
account in finalising these documents prior to submission for ethics approval”
Y Unclear whether CI had expectations for or prior experience of PPI; no challenges.
No PPI contributor interview
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Table 1 Continued
Trial ID
Status
(trial ended or ongoing)
Mode(s) Summary of planned activity*
PPI
plans fully
implemented? Accounts of ‘actual’ PPI activity†
102
Ended
Oversight + responsive
No PPI co-applicants
“At the outline proposal stage, this trial was submitted to the [name of funding body]
who sought the opinion of the [condition] Society. The [condition] Society
unequivocally confirmed their support of the proposed trial. The [condition] Society
have also confirmed their willingness to represent their members through steering
committee membership of the [name of trial] and to help the trialists in the
construction of the MREC application and patient information leaflets”
Y Seems to have expanded plans (in terms of dissemination, ie, press releases and
findings for participants). CI had expectations for and prior experience of PPI; no
challenges. No PPI contributor interview
6
Ongoing
Oversight + responsive
No PPI co-applicants
“The TSC will include an already identified patient. He will provide an informed
patient perspective. He is willing to assist us in the trial, and will be listed as a
member of the TSC. We will also work with [charity] to involve service users. This
will be done through our links with the [unit], which is co-directed by one of our
applicants, [name]. We will begin this process during the protocol set-up period”
Y CI had expectations for but unclear whether had prior experience of PPI; no
challenges. No PPI contributor interview
7
Ongoing
Oversight + managerial +
responsive
Had a PPI co-applicant
“We will include patients and carers as active participants in the research at all
stages. [Name] and [name] have taken the role of patient representatives during the
preparation of this research proposal. As the relevant service users are highly likely
to be frail, we will use innovative methods to allow full involvement. We will not
expect attendance at full research team meetings by patients or carers, although
our patient representatives may bring their views to the team meetings, following
meetings with individual or groups of service users in other forums. We identified
service users to be involved in this trial through the [names of 2 organisations]. Our
named co-applicant will attend Trial Management Group meetings throughout the
study in order to contribute the service user perspective at all stages. In addition,
[name] is a named co-applicant to the study and will play a role in ensuring that a
patient focus is maintained throughout the study. We also plan to seek further
views through a wider stakeholder group that will feed into the Trial Management
Group through a nominated representative”
Y Consulted separate panel of service users for specific issues. CI had expectations
for and prior experience of PPI; challenges (identifying/engaging the right people;
some less able to articulate their views; some wanting to do something impossible;
difficulty getting other staff to understand or prioritise PPI). No PPI contributor
interview
41
Ongoing
Oversight + managerial +
responsive
Had a PPI co-applicant
“A representative from [charity] has been involved in preparatory work and will be
nominated as a member of the TSC. A minimum of two users will be invited to be
part of the project team. A virtual user advisory group will be developed to provide
further user support as appropriate. User involvement will contribute to: TSC and
project management decisions on all stages of the project; project approval;
refinement of self-assessment tools and advice package, exercise intervention;
training events for health professionals; interpretation of findings; evaluation of user
involvement; dissemination”
Y Has PPI co-applicant. Trial has two PPI contributors although CI feels no strong
PPI input overall. Unclear whether CI had expectations for PPI; had no prior
experience of PPI; challenges (contributors with an ‘axe to grind’; contributors’ lack
of confidence about contributing at meetings). No PPI contributor interview
79
Ended
Oversight + responsive
No PPI co-applicants
No documented plans
NA Although no documented plans, the CI wanted PPI to sit on TSC and comment on
patient info leaflets. The CI felt that PPI started early. There were two types of
involvement: two contributors on the TSC; and then obtained views on information
sheets from relevant groups. CI had no previous experience of PPI; no challenges.
No PPI contributor interview
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Table 1 Continued
Trial ID
Status
(trial ended or ongoing)
Mode(s) Summary of planned activity*
PPI
plans fully
implemented? Accounts of ‘actual’ PPI activity†
76
Ongoing
Oversight + responsive
No PPI co-applicants
“The [organisation] has recently established a Research Advisory Group. This
Group, which includes key stakeholders with an interest in the research carried out
by [organisation] (patients, charities representing patients’ interests, general
practitioners, NHS commissioners, research funding organisations and a regional
[medical] network), has been set up to ensure that the clinical research carried out
in [organisation] is ethical, important, relevant, appropriately designed to meet the
needs of patients and the NHS. We anticipate the Group would have the
opportunity to influence important details of the project before recruitment starts. A
patient representative (we propose a member of the [advisory group]) will be invited
to join the TSC”
U Has PPI membership on TSC as planned; unclear whether plans to seek advice of
new advisory group prior to recruitment were implemented (although did approach
a group of patients from a previous trial about format/comprehensibility of
questionnaire). CI talked of a “tick box exercise” but also ensuring participants’
perspective; “overseeing the trial—a ‘safeguard’ rather than improving research.”
CI had expectations for but no prior experience of PPI; challenges (communication
and understanding). No PPI contributor interview
106
Ended
Oversight+responsive
No PPI co-applicants
“We have consulted widely, including with patients to seek their views on trial
design and relevant outcome measures. We have involved service users in the
design of the trial. We used the patient information pack and part of the
questionnaire that has been developed and validated in collaborative research with
the [institute] as a basis for in-depth interviews to identify patient perspectives on
trial design and outcomes. We have identified one service user, [name], who will
advise the trial management committee on patient perspectives”
Y No CI interview. PPI contributor had prior experience of PPI but felt she had made
no difference to the trial; no challenges
91
Ongoing
Oversight+responsive
No PPI co-applicants
“We have involved [name] who is a non-executive patient representative member of
[hospital trust] and who has co-ordinated consumers’ input into the scientific quality,
feasibility and practicality of the proposal. She will continue to participate in the
protocol design of the study and be a member of the TSC”
Y No CI interview. Plans expanded (in terms of the PPI contributor obtaining
feedback from “women’s groups”). PPI contributor had prior experience of PPI;
challenges ( just being confident enough to make your point)
Based on informants’ accounts, it was unclear whether the trial fully implemented or was implementing all plans.
Based on informants’ accounts, the trial did what planned in that PPI had been or was being fully implemented.
NA no documented plans.
*As described in the funding application and/or study protocol; includes justification of costs where data were available.
†As reported during informant interviews—any reference to tokenism; whether CI had prior experience of or personal expectations for PPI; whether CI mentioned challenges; whether PPI contributor mentioned
challenges.
‡PPI contributor was discussing two trials (ID 18 and 34) during the interview.
§Many trials utilised more than one form of PPI.
CI, chief investigator; PPI, patient and public involvement; TSC, trial steering committee; U=unclear; Y= yes.
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Oversight mode trials (n=6)
Oversight mode trials were those which conﬁned PPI
input to membership of TSCs. On the basis of informant
interview accounts, there were six trials that constrained
PPI to this mode of involvement, although three of
these had hinted at other modes in their applications. A
further application had been too vague to discern the
mode of planned PPI, and another had no documented
plans for PPI (table 1).
On the basis of informants’ accounts, all trials which
had documented plans for PPI membership on their
TSC had implemented this aspect of the plans.
Researcher interviews were available for four of these six
oversight trials and of the four, only one researcher
divulged any personal expectations for PPI in the trial.
Moreover, informants’ accounts raise concerns about the
motivations for including PPI in their applications and
the danger of assuming that contributors know what is
expected of them. For example, trial 36 had named a
‘patient representative’ as a member of the TSC at the
application stage then subsequently, in direct response
to peer reviewer comments, the team had indicated that
they would consider increasing the number of ‘patient
representatives’ on the TSC from one to two, in order to
provide ‘mutual support’. The team proceeded to
include two PPI contributors on the TSC, thereby
achieving their documented plans. Despite having prior
experience of PPI, however, the researcher divulged no
personal expectations for PPI within this particular trial
and referred to PPI as a ‘tick box’ exercise:
It was a requirement of...that we had representation on
our steering committee and therefore I went through that
[…] We can say [the PPI contributors] are there and
therefore it’s, if you like, ticking a political box. (CI 36)
The documentation for trial 2 included no plans for
PPI during the trial but did state that there had been
‘several stages of user involvement’ prior to the grant
application, “to conﬁrm that the research question is
pertinent to both the needs of the NHS and the NIHR
programme of research development.” Two grant
reviewers commented on the lack of ‘service user repre-
sentation’ on the team and suggested membership ‘on
the research team or steering group’. The TSC did
include PPI membership but during the interview the
researcher spoke of his initial ‘tokenism’ and ‘ignor-
ance’ about how PPI ‘should and could work’. When
asked about the expectations of their role, the PPI con-
tributors in two other oversight trials (115 and 96)
implied similar uncertainties when they spoke of not
knowing what was expected of them and of feeling
‘bewildered’ in meetings:
I can’t understand why they use me… they seem to ﬁnd
me useful but I just sit there bewildered. I’m there as a
sort of grey background while the others do all the
sparky stuff. (PPI 115)
In the next section we describe planned and imple-
mented PPI in 14 trials which incorporated a managerial
role of PPI. Unlike the six trials with a mainly oversight
mode, many of the managerial mode trials had utilised
more than one form of PPI.
Beyond oversight, into managerial mode (n=14)
Most of these 14 trials had indicated some type of man-
agerial involvement in the documented plans, usually to
include PPI contributors as co-investigators (table 1).
Two trials (4 and 27) did not have PPI contributors as
co-investigators but planned to include PPI contributors
on the trial management group, and interviews with
informants indicated that this had been implemented. It
was unclear in one ongoing trial whether there was a
PPI co-investigator, but documented plans stated that a
named PPI collaborator would be “directly involved in
decision making of trial processes and then relay back
information to user groups”; according to the PPI con-
tributor interview these plans were being implemented
(trial 18). Trial 10 had no documented plans for PPI but
the interview with the CI indicated that there was a PPI
co-investigator (trial 10).
Informants’ accounts indicated that all trials which had
planned a managerial mode of PPI did implement it
(table 1). This included trial 21, which had a PPI
co-applicant and documented plans to involve user groups
in developing information leaﬂets, consent forms, letters
and in questionnaire design. There was a budget for PPI
travel and expenses which is perhaps indicative of careful
planning. The documented plans stated that “user and
consumer groups were very keen that a user was a collabor-
ator on the grant application.” The applicants also
planned and included oversight PPI (TSC membership)
and expanded beyond their plans to include contributors
in recruitment, in the analysis and interpretation of
results, and in dissemination. Although we could not pin-
point from the informant interviews exactly what
prompted these additional PPI activities, the PPI contribu-
tor who we interviewed described his extensive previous
experience in similar roles and noted that his role in this
particular trial had ‘evolved’. He also explained that “I’m
there because I want to change things” (PPI 21) and this
proactive approach may have contributed to the expansion
of PPI in this particular trial. Correspondingly, the CI
spoke of wanting the PPI contributors to “feel welcomed
and valued as part of the group,” and had personal expec-
tations for PPI that included PPI contributors helping with
‘running the study’, ‘disseminating the results’ and that
‘they would stay involved’ and ‘feel able to speak out and
have their own opinion’:
We wanted them to offer to do things that they felt they
could do and feel happy to say if they didn’t feel they
could do certain things that might come their way. (CI 21)
There were several examples akin to this among trials
incorporating a managerial mode of PPI, in which CIs
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reported having personal expectations for PPI or in
which PPI contributors appeared to be an integral
member of the research team. However, one of the two
exceptions was trial 14, in which documented plans had
been to involve a PPI co-applicant “with an academic
interest in representing patients’ perspectives in the
design and conduct of health care research,” adding
that this individual would advise on “the development of
processes and materials which take into account patient
concerns.” Responses to the CI survey described the PPI
contributor as ‘a serial patient representative’. When
interviewed, the CI divulged no personal expectations
regarding PPI contribution, describing it as a ‘tick box
exercise’:
The funders were insistent on having patient representa-
tion and wanted to know what that representation was on
your grant submission. (CI 14)
In summary, most trials which planned a managerial
mode of PPI implemented it. However, as trial 14 shows,
simply having a PPI co-investigator is not necessarily a
guarantee of meaningful contribution if researchers
have no expectations for PPI or if contributors are
unable to provide the input that a particular trial
requires, for example because they are selected out of
convenience rather than to match trial needs. In the
next section we focus on the less formal, responsive,
form of PPI in which researchers ‘reach out’ for speciﬁc
PPI input as and when needed.
‘Reaching out’—responsive roles (n=14)
Fourteen trials embraced some form of responsive
involvement, although trial documents for two (10 and
79) had not indicated any plans for PPI (table 1). The
remaining 12 had stated in their documented plans
that they would, or already did, engage with PPI groups
or panels rather than just with the one or two indivi-
duals that was typical of oversight and managerial PPI.
Data from application forms, project descriptions and
informant interviews showed that this responsive activity
sometimes entailed seeking advice from PPI groups
prior to the application for funding. Informants noted
that many trialists continued to seek advice from such
groups during the trial regarding speciﬁc issues. Other
trials began a responsive approach once the trial had
begun, often as and when particular problems arose.
Most trials implemented all aspects of their documen-
ted plans but in one case (trial 76) it was unclear from
the CI interview whether speciﬁc plans to seek advice
of a new advisory group before recruitment were
implemented.
Trial 20 used responsive alongside managerial PPI,
including having a PPI co-applicant. The trial had
ended at the time of the interviews, and the researcher
stressed that the responsive PPI had been ‘crucial’ when
faced with speciﬁc problems. The CI explained that one
PPI contributor would attend research team meetings:
but I then reached out to other people in addition when
we needed more help […] I think what was crucial was
being able to get input, not in terms of regular intervals
but […] when you’ve got a problem. (CI 20)
Further illustrating the ﬂexibility that responsive PPI
allows, in her interview one of the PPI contributors on
the same trial (who on this particular trial had a man-
agerial role), advised researchers to ‘have some under-
standing’ of the needs of PPI contributors. She then
went on to refer to another contributor on the same
trial who did not attend project meetings but who oper-
ated in a more responsive mode outside of meetings. It
appeared this arrangement had evolved to accommo-
date the needs of the latter contributor, who, it seemed,
found meetings difﬁcult.
She didn’t really know what to do, so I think it was much
more a one-to-one conversation which is what she was
happy with rather than sitting in a committee. (PPI 20)
Documented plans for trial 7 involved a combination
of oversight, managerial and responsive modes. This
trial was collecting outcome data at the time of the
researcher interview, and PPI plans were being imple-
mented including consultation with a panel of service
users who advised on issues such as how to increase par-
ticipant response rates to the outcome questionnaire,
and on the promotional material that accompanied it.
When interviewed, the researcher spoke of her personal
expectations that PPI would help to maximise recruit-
ment, ensure the right outcomes were measured, and
help in interpreting the ﬁndings. There was no PPI con-
tributor interview but the researcher also spoke of
having to tailor ‘different ways of involving people’ in
PPI depending on the ‘population of interest’:
It might be children, people from disadvantaged groups
or older people [...] so you probably have to ﬁnd other
tailored ways of including people to make it effective. So
it’s not a one size ﬁts all. (CI 7)
The majority of those researchers interviewed who
described such ‘as and when’ contributions (10/12)
spoke of expectations for PPI, and tended to view
responsive modes as constructive. Only in one case (trial
101) did the researcher allude to the PPI within their
trial as a ‘tick box’ exercise.
Three trials undertook additional responsive PPI activ-
ity that had not been speciﬁed in their documented
plans. Trials 21 and 102 expanded on their plans by
involving PPI contributors in a broader range of activ-
ities than initially indicated, namely advising on recruit-
ment and interpretation and dissemination of study
ﬁndings. As with trial 21 (described in the Managerial
Mode section above), we could not determine from the
CI interview why plans for Trial 102 had been expanded,
and there was no PPI contributor interview for trial 102
to help illuminate this issue. The PPI contributor for the
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third trial (trial 91) mentioned that she sought the views
of ‘women’s groups’. This was additional to the docu-
mented plans for her to be involved in ‘protocol design
of the study’. As with Trial 21, this PPI contributor had
previous PPI experience and appeared to be a particu-
larly active member of the research team, and with con-
siderable knowledge of the relevant health condition.
In summary, most applicants implemented their docu-
mented plans for PPI regardless of the mode of planned
involvement. In ﬁve cases we were unable to discern
whether or not PPI plans were fully implemented,
although some PPI was achieved in these trials. Regardless
of whether PPI was implemented as planned or evolved,
most trial teams faced challenges and learnt lessons about
implementing PPI as they went along. We now turn to
their accounts of this learning and then use these to derive
practical advice for planning and implementing PPI.
Researchers on the challenges of PPI and lessons learnt
Most CIs spoke of the challenges they encountered in
implementing PPI (table 2) and things they would do
differently as a result. The involvement of trial investiga-
tors’ own patients as contributors was perceived to lead
to a ‘conﬂict’ (CI 20) between an investigator’s research
and clinical roles. This brought a risk that research
would “cross over into clinical care” (CI 6), and that
such contributors would be ‘out of their depth’ (CI 20)
and ﬁnd it difﬁcult to “say something which might imply
a criticism of their clinician” (CI 20). CIs talked about
the problems of failing to engage PPI contributors fully
or early enough to inform changes in study design, and
‘under-utilising’ (CI 101) PPI contributors by not involv-
ing them in the planning stages, thereby making PPI
less thorough or, as one informant noted, less ‘robust’
(CI 101). They reﬂected on the potential detrimental
consequences of such failings on the relationship
between researcher and PPI contributors, for example
being less likely to “form a bond and get loyalty”
(CI 14). Finding and engaging the right people with an
interest in and understanding of the research, and with
the necessary conﬁdence, commitment and impartiality
was another major stumbling block:
You hear that some consumers get involved […] because
they have a particular point of view or axe to grind […]
in those circumstances it could be very detrimental to a
trial, to be driven by somebody who has had a bad
experience […] and those are the ones you don’t want
on your team. (CI 5)
You’ve got trialists in the [meeting] who are trained to
run clinical trials. And then you’ve got one lay represen-
tative who may be slightly intimidated by everyone else,
who’ll not be able to truly give their views, may be slightly
overawed. (CI 14)
Researchers also pointed to the practical difﬁculties
that contributors experienced in attending meetings due
to geographical distance or time constraints (table 2).
They emphasised how teleconferences could be less con-
ducive to forming a relationship with PPI contributors
Table 2 Summary of challenges met by CIs and contributors to PPI in clinical trials
CI interviews (n=21) PPI contributor interviews (n=17)*
Challenges common to researchers and PPI contributors:
Failure to engage contributors fully or early Not being involved from the start;
Infrequent meetings
Contributors overawed/lacking confidence Feeling unqualified or overwhelmed
Failing to clarify to contributors what was expected of them Role expectations (being unsure what was expected
of you)
Worry about taking up contributor’s time
Contributors being ‘poached’
Time constraints
Being in demand by other research teams
Meeting attendance by PPI contributors Getting to meetings
Challenges unique to researchers or PPI contributors:
Finding the right people Jargon
Own patient as a PPI contributor (can lead to conflict between
clinical and research roles)
Interactions within team and being listened to
Communication difficulties due to age Concern about appearing confrontational
Change of PPI personnel Concern about appearing too ‘pernickety’
Getting other team members to understand/prioritise PPI Remembering ‘what side you are on’
Underestimating training needs of contributors
Worry that contributors may lose payment if receiving state
pension/benefits
Disagreement with funders about implementing contributors’
suggestions
*One PPI contributor was involved in and talked about two trials which were in this sample, and there were two trials for which we had two
PPI contributor interviews each.
CI, chief investigator; PPI, patient and public involvement.
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than face-to-face meetings. They also reported problems
relating to communication and mutual comprehension
between themselves and PPI contributors. Some
described PPI contributors as struggling to understand
the nature of research, or the distinction between
research and clinical practice, and one CI referred to his
own ‘naivety’ (CI 55) in underestimating how much train-
ing PPI contributors might need. CIs described difﬁcul-
ties getting other staff such as TMs to understand or
prioritise PPI. This included one CI who noted that some
investigators are unable to ‘cope’ with having a “working
relationship with service users” and “can’t let go of the
fact that [they] are people they study”:
It’s a mindset […] an attitude where you have an equal
partnership. You’re working together not studying these
people. You’re asking for their expertise and I’ve found
that some people who’ve worked with me, that comes
easily and some people absolutely never get it. (CI 20)
CIs remarked that they were unclear about what to
expect in relation to PPI and worried about taking up
the contributor’s time. External forces also played a part
in some cases: for example, one CI described PPI contri-
butors being ‘poached’ by other studies, a ‘ﬁght’ with
the university regarding paying a PPI contributor for his
time, and disagreement with funders when a contributor
wanted to add to the patient information sheet that he
was a PPI contributor on the project (CI 21).
CIs spoke of how they had learnt as the trial went along,
revealing that their ‘practice had evolved’ (CI 14) and their
skills had “changed beyond recognition […] now we’re
much better equipped […] but at the time when [trial]
started we had very little idea at all about what PPI involved
or how it would help or how it would work” (CI 2).
In light of these challenges, CIs spoke of how in future
they would involve more than one PPI contributor, in par-
ticular by using focus groups or panels of contributors
rather than individual contributors, enlist the help of
relevant charities, and conduct surveys or use social
media when there was a ‘burning question’ (CI 55). Use
of responsive PPI rather than individual contributors was
described as ‘gold standard’ PPI (CI 14), as this avoided
“the danger of having a single opinion” (CI 76), provided
structure for all parties, and helped to enhance the conﬁ-
dence of individual contributors.
I would certainly have more involvement and some kind
of framework around it […] a small user group and set
boundaries […] try to agree how often we should meet
and what peoples’ roles and responsibilities are […] and
provided more structure […] to make them feel that
their views are important, and their involvement is very
important, I think that would go a long way to easing the
process. (CI 41)
Many CIs indicated that they would extend PPI in future
by asking contributors to lead in the dissemination of
ﬁndings to relevant groups, help in the development of
research questions, study design, and involve PPI contribu-
tors as co-investigators. CIs placed particular emphasis on
how ‘crucial’ it was to have ‘early input’ (CI 14):
The most useful things are […] the design stage […]
RCTs you’ve got to plan ahead [...] after the development
phase you shouldn’t really be changing anything […] it
is during that development phase when decisions are
being made. (CI 115)
Early engagement and appreciation that their input into
the question is really important […] with retrospect and
for the future studies […] more involvement at the front
end, less in the middle and more at the end. (CI 2)
Finally, CIs reﬂected on the importance of ‘thinking
through’ plans and being clear about whether, what and
why PPI is needed for individual trials:
Be clear about the link between particular methods [of
PPI] and particular beneﬁts and challenges […] it’s not all
the same, there are so many ways of doing it but you have
to have good reasons for choosing how to do it. (CI 20)
“I don’t think it should be automatic that there must be PPI
involvement in every study, and different types of involve-
ment are necessary for different parts of study. Having a
core group is not necessarily the right thing because at dif-
ferent points there are different types of people and types
of involvement that would be useful. (CI 10)
Contributors on the challenges of PPI and suggestions for
improvement
Most PPI contributors mentioned challenges or difﬁcul-
ties linked to their involvement in the trial which may
inform future research teams in planning and imple-
menting PPI. Some of the contributors’ challenges paral-
leled CIs’ accounts while others were unique to the
contributors (table 2). While researchers referred to pro-
blems they had experienced in their communication with
contributors, a prominent issue exclusively mentioned by
contributors related to the problems they experienced
with ‘jargon’ and the technical language that was used in
trials such as statistical or medical terminology and acro-
nyms. Several contributors suggested remedies such as
supplying a list of acronyms or a booklet of research
terms, or simply that “if they’re going to use jargon,
explain it” (PPI 64). A further idea was that the person
chairing meetings could try to ensure that discussion
about statistical issues or other areas of technical expert-
ise were translated and summarised adequately.
Contributors talked about difﬁculties in interacting with
researchers, including not always feeling listened to by
everyone. One contributor who had been invited by her
consultant and had previous experience of PPI implied
that ‘some doctors’ were unwilling to understand the per-
spectives of patients (PPI2 27). Another felt that female
researchers were more understanding than males regard-
ing problems with travelling or feelings of insecurity,
while a further contributor alluded to how in meetings
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the team sometimes talked about patient experiences in
a ‘dispassionate’ way, and although this was not a
problem for the individual contributor she felt it might
be for others (PPI1 27).
Some of the challenges that contributors described
echoed those that the CIs has raised. These included
lack of clarity about roles, and the difﬁculties contribu-
tors experienced in attending meetings, for instance
because of a health condition. Such practical difﬁculties
could give rise to additional complexities. For one con-
tributor, infrequent meetings meant “not much to build
a relationship on” and while academics worked closely
together, she had to “work quite hard to keep up”
(PPI 16). Contributors also talked about wanting to be
more involved in between annual meetings, in ‘shaping
the bid’ (PPI 20) so that it was less focused on the
primary clinical outcome, in seeing the intervention
itself, and to have initial brieﬁng meetings at the outset
of their involvement. Finally, one contributor described
it as a ‘downfall’ that he was not receiving feedback or
‘thank yous’ and commented on how important it was to
make PPI contributors ‘feel valued’ (PPI 34).
DISCUSSION
Main findings
The path to PPI: plans, actions and complications
This is the ﬁrst study to examine whether plans for PPI, as
documented in RCT grant applications, are being imple-
mented. On the basis of the accounts of researchers and
PPI contributors we found that most trialists are indeed
putting their plans to action, although in some cases the
plans were minimal and relatively easy to execute. There
were a few trials for which we were unable to conﬁrm
whether plans were implemented in full, but all did
incorporate some PPI. Many trials implemented multiple
modes of PPI, which is surprising and encouraging given
that PPI was less prominent when the proposals for the
trials in this cohort were being developed. CIs encoun-
tered complications from which they learnt valuable
lessons. Uncertainty about what to expect of PPI and emer-
gent challenges with their trials meant that involvement
had to evolve. Difﬁculties ﬁnding and retaining suitable
contributors and engaging in PPI ‘too little too late’ led tri-
alists to say they would do things differently in future.
Many reﬂected on how they would aim for earlier engage-
ment next time and seek involvement from a more diverse
source such as patient panels or focus groups. PPI contri-
butors themselves mentioned that becoming involved after
the trial had begun, or infrequently, resulted in missed
opportunities for them to contribute. Some referred to
uncertainty about their role and many struggled with
jargon, an enduring problem despite the availability of
apparently straightforward solutions.
Pressured into PPI?
Regardless of statements about PPI in their funding appli-
cation some trialists had no expectations of what PPI
might achieve, and their only motivation for including PPI
was a belief that it was necessary or would help to secure
funding for their trial. Such strategic minimalism may be
an inevitable side-effect of policies to promote or require
PPI in trials. It may also reﬂect researchers’ professed inex-
perience of PPI. A small number of trials did not have
documented plans for PPI but all did nevertheless include
some PPI, possibly inﬂuenced by reviewer and panel com-
ments. However, one of these trials had been through
several stages of PPI prior to the grant application and was
requested to implement further PPI over the course of the
trial. This highlights the predicament of researchers whose
trial may have beneﬁted from considerable PPI prior to
funding (eg, in feasibility and pilot work) and forecast that
they would need relatively little PPI during the trial itself,
only to ﬁnd that funders insist on PPI at all stages. Many
informants believed formative PPI prior to funding was
one of the most useful, credible aspects of PPI. Particularly
in cases where there has been extensive PPI prior to the
main trial, it is important for all members of the research
community to consider whether plans for ongoing PPI
match the needs of a particular trial and at what stage(s)
further PPI would be appropriate.
Previous research
We found no previous reports on the extent to which
documented plans for PPI within trials were subsequently
implemented. There have been several accounts of chal-
lenges involved in implementing PPI which, while not in
a trials context, endorse our ﬁndings. For instance, recent
reports have referred to tokenism,28 29 or highlighted the
potential challenges in identifying suitable individuals
who are impartial and able to understand research
methodologies, retain an interest, and commit long-
term;15 17–19 30 of researchers having little experience of
PPI and being uncertain about what to expect;15 18 31 and
of jargon-related problems.19 32 33 INVOLVE suggest that
PPI contributors would beneﬁt from a ‘glossary of tech-
nical terms’,17 again something reﬂected in the sugges-
tions from contributors within our study. Staley4 refers to
the challenge of ensuring that involvement is meaningful
and not simply tokenistic. Findings from the EPIC project
regarding PPI training needs suggest that while infor-
mants were broadly receptive to PPI training for research-
ers, there was considerable reluctance regarding the
training of PPI contributors, with a preference for ‘infor-
mal inductions’. The health services researchers in a pre-
vious qualitative interview study varied in how they
interpreted PPI policy and in their PPI ‘working practices’
and referred to how PPI brought a ‘fear of the
unknown’.31 This study also points to a ‘know-do’ gap,
whereby researchers’ talk of the importance and value of
PPI in the ‘ideal’ world stood in contrast to their experi-
ences of ‘the reality’ of implementing PPI in practice.29
The timing of involvement has been recently high-
lighted3 20 and is clearly an ongoing challenge which is
exacerbated by ﬁnancial and time constraints8 32 particu-
larly during the grant-writing stage.
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Study limitations
We used a historical cohort of trials that had been
funded 4–8 years ago. Even in that short time the
emphasis on PPI has grown and our ﬁndings may not
reﬂect the planning and implementation of PPI in
trials funded more recently. Some of the trials in our
sample were also initiated and completed some time
before the interviews. However, this limitation is offset
somewhat by the inclusion of ongoing trials in which
PPI activity was recent and therefore easier to recollect.
There were ﬁve trials for which it was not possible to
determine whether all documented PPI plans had been
fully implemented or not. In some cases informants
clearly struggled to recall events for trials which had
ended several years previously or where researchers
were involved in a number of trials simultaneously. We
explored with informants how PPI contributors were
involved in the trials but did not directly quiz CIs about
why certain plans within their application were not
implemented. This was intentional as we did not want
to pose questions which may have seemed accusatory
and have a detrimental impact on the rapport between
informant and interviewer or risk informants becoming
defensive. While some trialists seem to have expanded
on their plans for PPI once the trial was underway
there may, conversely, have been instances in which
plans were not fully documented within the grant
application.
Implications and tips for the trials community
We have used the insights of informants to generate prac-
tical tips which may help future trialists and PPI contribu-
tors (box 1). We envisage that these be considered
alongside previously published guidance for PPI in
trials17 20 and consensus principles for PPI in health
research.34 35 The tips generated from evidence in our
study cover the importance of early planning, of timely
and ﬂexible PPI, and of communication and clariﬁcation
of roles. They also stress the need to consider the difﬁcul-
ties posed by the use of ‘jargon’, and problems contribu-
tors experience in understanding certain aspects of the
research process. The difﬁculties contributors experience
with specialist or technical terminology have been widely
reported.19 32 33 Our data suggest that this problem has
existed for some considerable time, and we outline the
practical solutions suggested by PPI contributors. The
tips in box 1 could be used to inform PPI training and
could be helpful in other types of health research. Given
that the usefulness of the points in box 1 depends on
researchers’ willingness to genuinely engage with PPI,
the tips we present might also assist funding bodies and
grant reviewers in determining whether submitted plans
are ﬁt for purpose. A study of the UK health and social
care research community has recently informed the
development of a Public Involvement Impact Assessment
Framework (PiiAF), which emphasises the value of well
thought-through planning before implementing PPI as
well as the subsequent evaluation of its impact,36 and
INVOLVE17 have emphasised the importance of clear
guidance about roles. However, researchers also need
some scope for ﬂexibility and contingency in planning
PPI: our ﬁnding that some trialists expanded their some-
times already detailed plans supports the need for ﬂex-
ible and iterative approaches to PPI in order to
accommodate the unexpected and respond to opportun-
ities and difﬁculties as they arise.
Ticking several boxes could equate to expensive token
gestures: implications for funders
Our ﬁndings endorse recent revisions to the NIHR’s
standard application form, which now require applicants
to clearly deﬁne their proposed PPI activity. Asking
researchers to specify and explain the type of involve-
ment they envisage and what they expect it to achieve is
a step in the right direction and should help to minim-
ise ‘tick box’ tactics and token gestures. However, the
risk of strategic minimalism remains if plans are not
afforded careful, context-speciﬁc consideration by
funders and reviewers. Equally, there is a risk of inadvert-
ent PPI proﬂigacy, that is, the encouragement of elabor-
ate plans for PPI that are disproportionate to the needs
of a trial. Ticking several boxes rather than just one box
could equally be a token gesture, as well as an expensive
one. Therefore, researchers might be encouraged to
think just as much about why, how and when PPI will be
useful, as about what and how much PPI.
Researchers are also now asked to describe, in their
grant applications, any PPI activity that they have under-
taken prior to submitting the application. Funding is avail-
able to support preapplication PPI, for example the
UK-based NIHR Research Development Service offers very
small grants, which others have found to be helpful.37 38
However, these grants are not easily or quickly accessible,
particularly for those working to the typically tight dead-
lines of funding calls. Paradoxically, this renders preappli-
cation PPI the most difﬁcult to implement, even though
our ﬁndings indicate that it is often most useful at this
stage. Innovative organisations that involve patients at a
meta-trial level in research priority setting http://www.
lindalliance.org/Patient_Clinician_Partnerships.asp and
in schemes such as COMET (Core Outcome Measures in
Effectiveness Trials)39 40 which promotes the involvement
of patients in developing ‘core outcome sets’, are provid-
ing knowledge and resources that individual trials can use.
However, at the level of individual trials infrastructural
support for early PPI is also needed. While there have
been innovations in this area, for example the US-based
Patient-Centred Outcomes Research Institute has
recently announced a number of ‘Pipeline to Proposals’
Engagement Awards,6 such moves are relatively novel, and
similar steps by other organisations would be beneﬁcial. As
well indicating the need for structures and resources to
support PPI, our ﬁndings point to the importance of PPI
that is ﬁt for purpose, realistic and proportionate. We
found that trialists who fully implemented a primarily over-
sight mode of PPI perceived little value in this involvement
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—a related article from our study will fully explore the per-
ceived impact of PPI in this cohort. While oversight PPI
seemed limited in terms of its practical impact, arguably it
may serve important ethical and moral functions.
However, in order to avoid inadvertently promoting PPI
that is devoid of any function for researchers and contribu-
tors, as we note above, funders should take full account of
any PPI which has taken place prior to funding applica-
tions as well as encourage applicants to justify future plans
for involvement. The NIHR HTA programme states:
Box 1 Tips for planning and implementing patient and public involvement (PPI) in clinical trials
Early PPI
“You’ve got to plan ahead”
▸ Begin planning PPI and consulting with contributors when starting to plan the trial.
▸ Consider including PPI contributors in managerial roles for example, as co-investigators.
Researchers and PPI contributors emphasised how early and regular involvement allowed contributors to input more effectively. PPI prior to
the trial (eg, in contributions to grant writing, trial design, feasibility studies) was a key aspect of PPI, and in some cases the most important
one.
Flexible PPI
“One size does not fit all” “Reaching out was crucial”
▸ Consider whether oversight PPI (eg, on a trial steering committee) is sufficient to meet trial needs.
▸ Involve more than one or two PPI contributors, more than once or twice a year.
▸ ‘Reach out’ and make use of multiple modes of PPI, including responsive PPI.
PPI is context-specific so it is important to tailor PPI to the emergent needs of trials and be creative to encourage active engagement.
Researchers felt that involving contributors beyond an oversight role, that is, not just as a member of the steering committee but in a man-
agerial or responsive capacity helped to foster meaningful PPI. In terms of responsive PPI, liaison with relevant patient panels or groups
may be particularly helpful when more diverse perspectives or wider consensus is needed; individuals might also consider whether surveys
(eg, of support group members) would be useful in answering ‘burning questions’, for example, regarding the acceptability of timing or
format of interventions or data collection.
Communication, clarification and interaction
“I can’t understand why they use me. I just sit there bewildered”
▸ Negotiate with contributors at an early stage about what they can bring to the trial and what they want to bring
▸ Determine whether this matches the trial’s needs and clarify roles and expectations
▸ Be sensitive to contributors’ needs and preferences
Communication between researchers and PPI contributors is crucial at the outset to clarify roles and expectations, and throughout the trial
to optimise engagement and provide feedback about contributions. It may be that particular contributors do not have the insights a trial
needs, or maybe trialists need to rethink their plans for PPI in the light of experience. Researchers should avoid seeming “dispassionate”
during meetings when discussing a particular illness or condition that impacts on the lives of PPI contributors, and make a genuine effort to
understand contributors’ points of view.
Language of research
“Break it down into a language everybody understands.”
▸ Minimise and explain jargon;
▸ Provide glossaries and ‘translations’ where applicable.
Researchers and contributors should discuss their written and verbal communication preferences and how to minimise and explain jargon.
Suggestions for minimising jargon included lists of acronyms or glossaries of research terms. PPI contributors should be prepared to speak
up if there is a problem and, with the help of researchers, be willing to acquaint themselves with specialist terms over time.
Budgeting for PPI
“University didn’t want to pay him the money” “We had money in the pot but only for one PPI”
▸ Budget for PPI—think about contributors’ time plus expenses.
▸ Explore opportunities for pretrial support for PPI.
Well thought-through plans will help inform how much to ‘cost in’ for PPI. Consult with administrators in your organisation at an early stage
to iron out processes for payments to PPI contributors. Talk to contributors to make sure they will be happy to accept reimbursement
beyond expenses. Find out whether there are any local or national resources to support PPI prior to funding applications.
Fit for purpose PPI
“The person we chose had very little engagement, it struck me as a complete waste of time”
▸ Agree what type of PPI would be appropriate and understand why.
▸ Consider benefits of involving those with experience of the condition.
▸ Recognise potential drawbacks of involving those under current care of the researcher.
Think through plans for PPI and centre them round the aims and needs of the trial. Agreement about and understanding of what and why
PPI is needed will help in planning it. Involving people with experience of the condition, intervention or service where applicable may be par-
ticularly germane in identifying research priorities and enhancing trial design. However, the inclusion of patients under the current care of a
team member may lead to difficulties for researchers as well as contributors.
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“While patient and public involvement (PPI) may not
always be needed for all types of research, it is
always relevant for HTA trials.” http://www.nets.nihr.ac.
uk/__data/assets/pdf_ﬁle/0003/77160/Preparing-a-full-
application-for-the-Clinical-Trials-and-Evaluation-Board.
pdf (last accessed 9 March 2014). Even if there is consen-
sus that PPI is relevant for all trials, it may not be relevant
at all stages of all trials. Equally, funders may wish to con-
template how ‘contingency’ resources could be made avail-
able for those trials that encounter unexpectedly intense
needs for PPI over the course of their implementation.
Our ﬁndings add fuel to recent drives and initiatives
to promote the assessment and reporting of PPI
processes6 28 30 http://www.journalslibrary.nihr.ac.uk/
authors/report-preparation/report-contents/14 includ-
ing the GRIPP checklist.41 The CONSORT (Consolidated
Standards of Reporting Trials) Statement, which was estab-
lished speciﬁcally to encourage adequate reporting of
RCTs, does not cover PPI. We suggest that consideration
be given to incorporating advice on reporting of PPI in
the main CONSORT checklist, so that reference to PPI is
incorporated within the main reports of trials, alongside
separate detailed reports on PPI, in line with the GRIPP
checklist. If, in planning their PPI, trialists are prepared to
consider and report its outcomes not only in terms of what
happened and how, but also how this matched the needs
of the trial, whether any complications arose or adapta-
tions were made, and what lessons were learnt, then the
evidence base will grow and the research community as a
whole can learn. The EPIC project has highlighted the
value of listening to the accounts of PPI contributors as
well as researchers, and this should feed into the evalu-
ation and reporting of PPI.
Conclusions
While most trialists fully implemented their documented
plans for PPI there were traces of a minimalist approach.
Planning and engaging PPI contributors early, and
beyond a primarily oversight role, seems to be the most
salient message from this analysis. At the same time
some degree of ﬂexibility within plans is prudent, and
making allowances for the unexpected may help all sta-
keholders to make the most of PPI. The involvement of
investigators’ current patients as PPI contributors should
be given cautious consideration as there is the potential
for conﬂict between clinical and research roles. PPI
activity prior to funding is as integral to meaningful
involvement as PPI activity during trials, and more so in
some cases. Proper and ﬂexible planning by research
teams will be instrumental in helping them to monitor,
adapt and report PPI during and after trials, and in
helping the research community as a whole learn how to
optimise PPI.
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